Daily Cosmetic Research Analysis
Analyzed 41 papers and selected 3 impactful papers.
Summary
Analyzed 41 papers and selected 3 impactful articles.
Selected Articles
1. Role of LDHA in senescent fibroblast exosomes promoting ferroptosis via histone lactylation-mediated ACSL4 regulation in skin photoaging.
Senescent fibroblast-derived exosomes deliver LDHA that increases histone H3K18 lactylation at the ACSL4 promoter, upregulating ACSL4, activating ferroptosis, and accelerating photoaging. LDHA inhibition reduced ferroptosis and tissue damage in vitro and in UVB-irradiated mice, while exogenous lactate partially rescued effects.
Impact: This work uncovers a previously unappreciated metabolic–epigenetic axis driving photoaging, offering tractable targets (LDHA, lactylation, ACSL4/ferroptosis) for anti-photoaging interventions.
Clinical Implications: Although preclinical, targeting LDHA-lactylation-ACSL4 signaling or exosome trafficking could inform the development of topical or procedural anti-photoaging strategies and biomarkers of treatment response.
Key Findings
- UVB-induced senescence upregulated LDHA and increased exosomal LDHA delivery to recipient keratinocytes.
- Exosomal LDHA elevated lactate and histone H3K18 lactylation, enriching lactylation at the ACSL4 promoter and boosting ACSL4 transcription.
- LDHA knockdown/inhibition reduced ACSL4 and ferroptosis; exogenous lactate partially rescued; in vivo, LDHA intervention attenuated UVB-induced collagen degradation and ferroptosis.
Methodological Strengths
- Multi-modal validation across in vitro (fibroblasts, HaCaT cells) and in vivo UVB mouse models.
- Mechanistic dissection using siRNA knockdown, pharmacologic inhibitors (FX11, Ferrostatin-1), RNA-seq, and ChIP-qPCR.
Limitations
- Preclinical study without human clinical outcomes; generalizability to diverse skin types remains uncertain.
- Potential off-target effects of inhibitors and limited reporting of sample sizes for some in vivo endpoints.
Future Directions: Test topical/systemic LDHA or lactylation modulators and ferroptosis inhibitors in translational models; develop biomarkers (H3K18la, ACSL4) for clinical trials of anti-photoaging therapies.
OBJECTIVE: This study aimed to elucidate the mechanism of Lactate Dehydrogenase A (LDHA) in senescent fibroblast-derived exosomes during skin photoaging, focusing on the molecular pathway by which it regulates Acyl-CoA Synthetase Long-Chain Family Member 4 (ACSL4) expression through histone lactylation, thereby inducing ferroptosis and accelerating skin photoaging. METHODS: An ultraviolet B (UVB)-induced senescence model was established using human foreskin fibroblasts. Exosomes were isolated from senescent fibroblasts and characterized. Their features and uptake were assessed using Western blot, transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and immunofluorescence. Small interfering RNA was employed to knock down LDHA and ACSL4 gene. Pharmacological inhibitors (FX11, Ferrostatin-1) and sodium lactate rescue experiments were utilized. Lactate levels, histone H3K18 lactylation modification, ACSL4 transcriptional activity, and ferroptosis markers were detected to assess the effects of ACSL4 gene lactylation on ferroptosis. The biological effects of exosomal LDHA in photoaged tissue were validated using an in vivo UVB-irradiated mouse model. RESULTS: UVB irradiation induced fibroblast senescence and significantly upregulated LDHA expression. Exosomes from senescent fibroblasts were effectively taken up by HaCaT cells, leading to increased lactate levels and enhanced histone H3K18 lactylation in recipient cells. LDHA knockdown or inhibition downregulated ACSL4 expression and suppressed ferroptosis, whereas exogenous lactate partially restored these effects. RNA sequencing and ChIP-qPCR results indicated that LDHA-mediated lactylation modification was enriched at the ACSL4 promoter region, enhancing its transcriptional activity. In vivo experiments further confirmed that senescent exosomes accelerated UVB-induced skin collagen degradation and ferroptosis, while LDHA intervention significantly alleviated photoaging damage. CONCLUSION: Senescent fibroblast-derived exosomes deliver LDHA, promoting histone lactylation modification, which upregulates ACSL4 expression and activates the ferroptosis pathway, ultimately accelerating skin photoaging. This study reveals the coupling mechanism between metabolic signaling and epigenetic regulation in skin aging, providing new molecular targets and a theoretical basis for anti-photoaging therapy.
2. Aesthetic techniques for melanocytic nevus management: clinical outcomes, cosmetic satisfaction, and safety-a systematic review and meta-analysis.
Across 46 studies (4,201 lesions), surgical excision achieved the highest clinical clearance (96.4%) and lowest recurrence (2.1%), while laser-based modalities—especially Er:YAG—delivered the best cosmetic satisfaction. The findings quantify trade-offs between histologic certainty/clearance and cosmesis and guide technique selection by nevus subtype.
Impact: This synthesis provides comparative, quantitative evidence to balance clearance/recurrence against cosmetic outcomes in common aesthetic procedures, informing shared decision-making.
Clinical Implications: Use surgical excision when complete removal and histopathologic assessment are priorities; consider Er:YAG or CO2 lasers when cosmetic outcome is paramount, with counseling about recurrence risk and need for follow-up.
Key Findings
- Surgical excision yielded the highest pooled clinical clearance (96.4%) and the lowest recurrence (2.1%).
- Laser treatments provided superior cosmetic satisfaction, with Er:YAG laser scoring highest, followed by CO2-based modalities.
- Subgroup analyses by nevus subtype and modality support tailored technique selection.
Methodological Strengths
- PRISMA-guided systematic review with random-effects meta-analysis and prespecified subgroup analyses.
- Risk of bias assessed using RoB2 for trials and Newcastle–Ottawa Scale for observational studies.
Limitations
- Heterogeneity in outcome definitions, follow-up durations, and cosmetic scoring across studies.
- Mixture of study designs; limited randomized head-to-head comparisons; potential publication bias.
Future Directions: Conduct head-to-head RCTs with standardized core outcomes (clearance, recurrence, validated cosmetic PROs) and adequate follow-up to refine modality selection by nevus subtype.
BACKGROUND: Melanocytic nevi are among the most frequently treated lesions in aesthetic dermatology. Various techniques are used for cosmetic or diagnostic purposes. However, comparative evidence regarding treatment efficacy, recurrence risk, cosmetic outcomes, and safety remains inconsistent. OBJECTIVE: To systematically evaluate and compare clinical clearance, recurrence rates, cosmetic outcomes, and adverse events associated with aesthetic techniques used for the removal of melanocytic nevi. METHODS: A systematic search of PubMed, Scopus, Web of Science, ScienceDirect, Wiley, and Google Scholar was conducted for studies published between January 2000 and May 2025. Studies reporting outcomes of surgical or aesthetic interventions for benign melanocytic nevi were included. Data extraction followed PRISMA 2020 guidelines. A random-effects meta-analysis was performed to pool estimates of clinical clearance, recurrence, and cosmetic satisfaction. Subgroup analyses were conducted according to nevus subtype (junctional vs. intradermal) and treatment modality. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool for randomized trials and the Newcastle-Ottawa Scale for observational studies. RESULTS: A total of 46 studies involving 4,201 lesions were included. Surgical excision demonstrated the highest clinical clearance rate (96.4%; 95% CI 92.1-99.2) and the lowest recurrence rate (2.1%). Laser-based treatments produced the most favorable cosmetic outcomes, with Er:YAG laser achieving the highest satisfaction score (8.8/10), followed by CO CONCLUSION: Surgical excision remains the most reliable method for complete melanocytic nevus removal and histopathologic assessment but may yield less favorable cosmetic outcomes. Laser-based treatments, particularly Er:YAG and CO
3. Heterogeneity in Clinical Outcomes Reporting in Minimally-Invasive Facial Rejuvenation: Is It Time for a Core Outcomes Set?
Among 242 RCTs in minimally invasive facial rejuvenation, investigators used 79 clinician scales, 69 PROs, and 53 objective metrics, with no single outcome used in >40% of trials. Marked heterogeneity—even within the same modality and facial region—and variation by region and funding underscore the need for a standardized core outcome set.
Impact: By quantifying outcome-reporting heterogeneity across modern RCTs, this review provides the empirical basis and urgency for a field-wide core outcomes set that can improve trial comparability and evidence synthesis.
Clinical Implications: Until a core outcome set is adopted, clinicians should interpret aesthetic RCTs cautiously, prioritizing studies with transparent, validated measures; trialists should harmonize endpoints and include both standardized PROs and objective metrics.
Key Findings
- Across 242 RCTs, 79 clinician-reported scales, 69 PRO instruments, and 53 objective outcomes were identified.
- No single investigator- or patient-reported outcome was used in more than 40% of trials.
- Outcome definitions and measures varied by treatment region and funding source, indicating systemic heterogeneity.
Methodological Strengths
- Comprehensive capture of RCTs (2020–2025) focused on minimally invasive facial/neck rejuvenation.
- Systematic identification and classification of investigator scales, PROs, and objective metrics.
Limitations
- Descriptive synthesis without meta-analysis; does not test or validate a proposed core outcome set.
- Potential publication and selection biases inherent to available RCTs.
Future Directions: Develop and Delphi-validate a core outcome set (COS) for aesthetic rejuvenation trials, guided by COSMIN/COMET, and promote adoption via registries and CONSORT extensions.
INTRODUCTION: Outcome measurement in aesthetic medicine is complicated by subjective definitions of beauty, psychosocial factors, and a lack of standardized assessment metrics. Outcome reporting heterogeneity limits physicians' ability to synthesize results from multiple studies. The purpose of this study was to identify the outcomes and outcome scales used in minimally-invasive facial rejuvenation clinical trials to determine the degree of outcome heterogeneity. METHODS: A systematic review was conducted to identify all randomized control trials published in 2020-2025 focusing on non-operative or minimally-invasive facial and neck rejuvenation treatments. We identified outcome measurements reported in each study, including investigator assessment scales, patient-reported outcome scales, and objective outcomes and metrics. RESULTS: Our search identified 242 articles for inclusion. From these, we identified 79 investigator assessment scales, 69 patient-reported outcome scales, and 53 objective outcomes reported. No investigator-reported or patient-reported outcome was used in greater than 40% of trials, and within studies comparing the same treatment type applied to the same facial region, there existed substantial heterogeneity in definitions of treatment efficacy. Furthermore, differences in reported measures existed between regions and funding sources. CONCLUSIONS: There is substantial heterogeneity in outcomes reporting among facial rejuvenation studies. Clinicians, researchers, and industry stakeholders should strive to develop a core outcome set to ensure that meaningful and consistent outcomes are reported in all clinical trials.